FDA Classification Systems
The FDA categorizes peptides into distinct regulatory pathways that researchers must understand. Approved peptides like semaglutide and oxytocin have undergone full clinical trials and are legally prescribed. Investigational peptides like kisspeptin-10 and larazotide are in clinical development but not yet approved.
Research vs. Prescription Distinction
Compounding-only peptides like sermorelin can be legally prescribed by doctors through specialized pharmacies. Cosmetic ingredients like GHK-Cu and matrixyl have different regulatory oversight focused on topical safety rather than systemic effects.
Gray Market Realities
Many peptides exist in regulatory gray areas. Research chemical suppliers often sell peptides "not for human consumption," creating legal ambiguity. Understanding these distinctions helps researchers navigate compliance requirements and assess quality standards.
Staying Informed
Regulatory status can change rapidly. The FDA periodically reviews peptide classifications, and new clinical data can shift regulatory pathways. Researchers should regularly check FDA databases and stay updated on enforcement actions.
This information is for research purposes only and not medical advice. Always consult regulatory experts for compliance guidance.